NVAX vs. TWST, DNLI, IOVA, RLAY, ADPT, EXEL, HALO, IONS, MDGL, and ALKS
Should you be buying Novavax stock or one of its competitors? The main competitors of Novavax include Twist Bioscience (TWST), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA), Relay Therapeutics (RLAY), Adaptive Biotechnologies (ADPT), Exelixis (EXEL), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), and Alkermes (ALKS). These companies are all part of the "medical" sector.
Novavax (NASDAQ:NVAX) and Twist Bioscience (NASDAQ:TWST) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, community ranking, risk, media sentiment and profitability.
Twist Bioscience has lower revenue, but higher earnings than Novavax. Twist Bioscience is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.
Novavax presently has a consensus target price of $17.50, suggesting a potential upside of 25.36%. Twist Bioscience has a consensus target price of $42.50, suggesting a potential downside of 1.57%. Given Novavax's higher possible upside, analysts plainly believe Novavax is more favorable than Twist Bioscience.
53.0% of Novavax shares are held by institutional investors. 0.9% of Novavax shares are held by company insiders. Comparatively, 3.9% of Twist Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Novavax has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500.
In the previous week, Novavax had 15 more articles in the media than Twist Bioscience. MarketBeat recorded 21 mentions for Novavax and 6 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.11 beat Novavax's score of 0.53 indicating that Twist Bioscience is being referred to more favorably in the news media.
Novavax received 754 more outperform votes than Twist Bioscience when rated by MarketBeat users. Likewise, 74.14% of users gave Novavax an outperform vote while only 56.69% of users gave Twist Bioscience an outperform vote.
Novavax has a net margin of -40.01% compared to Twist Bioscience's net margin of -69.24%. Novavax's return on equity of 0.00% beat Twist Bioscience's return on equity.
Summary
Novavax beats Twist Bioscience on 11 of the 18 factors compared between the two stocks.
Get Novavax News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
